BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30112638)

  • 1. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
    Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
    Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The true prognosis of resected distal cholangiocarcinoma.
    Courtin-Tanguy L; Rayar M; Bergeat D; Merdrignac A; Harnoy Y; Boudjema K; Meunier B; Sulpice L
    J Surg Oncol; 2016 Apr; 113(5):575-80. PubMed ID: 26776934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.
    Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A
    Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma.
    Courtin-Tanguy L; Turrini O; Bergeat D; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
    HPB (Oxford); 2018 May; 20(5):405-410. PubMed ID: 29208352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.
    Wang L; Deng M; Ke Q; Lou J; Zheng S; Bi X; Wang J; Guo W; Li F; Wang J; Zheng Y; Li J; Cheng S; Zhou W; Zeng Y
    Cancer Med; 2020 Apr; 9(8):2674-2685. PubMed ID: 32072774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
    Akahoshi K; Ban D; Kuboki R; Oba A; Ono H; Mitsunori Y; Kudo A; Tanaka S; Tanabe M
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1108-1115. PubMed ID: 30242888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.
    Li XH; Zhao CY; Zhou EL; Lin XJ
    BMC Cancer; 2022 Nov; 22(1):1159. PubMed ID: 36357848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
    Oncology; 2019; 96(6):290-298. PubMed ID: 30909286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study.
    Strijker M; Belkouz A; van der Geest LG; van Gulik TM; van Hooft JE; de Meijer VE; Haj Mohammad N; de Reuver PR; Verheij J; de Vos-Geelen J; Wilmink JW; Groot Koerkamp B; Klümpen HJ; Besselink MG;
    Acta Oncol; 2019 Jul; 58(7):1048-1055. PubMed ID: 30907207
    [No Abstract]   [Full Text] [Related]  

  • 10. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio.
    Dasari BV; Roberts KJ; Hodson J; Stevens L; Smith AM; Hubscher SG; Isaac J; Muiesan P; Sutcliffe RP; Marudanayagam R; Mirza DF
    HPB (Oxford); 2016 Apr; 18(4):332-8. PubMed ID: 27037202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium.
    Ethun CG; Lopez-Aguiar AG; Pawlik TM; Poultsides G; Idrees K; Fields RC; Weber SM; Cho C; Martin RC; Scoggins CR; Shen P; Schmidt C; Hatzaras I; Bentrem D; Ahmad S; Abbott D; Kim HJ; Merchant N; Staley CA; Kooby DA; Maithel SK
    J Am Coll Surg; 2017 Apr; 224(4):406-413. PubMed ID: 28017812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms.
    Nappo G; Galvanin J; Gentile D; Capretti G; Pulvirenti A; Bozzarelli S; Rimassa L; Spaggiari P; Carrara S; Petitti T; Gavazzi F; Zerbi A
    Pancreatology; 2021 Aug; 21(5):950-956. PubMed ID: 33795194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robotic versus open pancreaticoduodenectomy for distal cholangiocarcinoma: a multicenter propensity score-matched study.
    Xu S; Zhang XP; Zhao GD; Zou WB; Zhao ZM; Hu MG; Gao YX; Tan XL; Liu Q; Liu R
    Surg Endosc; 2022 Nov; 36(11):8237-8248. PubMed ID: 35534733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.
    Hester C; Nassour I; Adams-Huet B; Augustine M; Choti MA; Minter RM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Yopp AC
    J Gastrointest Surg; 2018 Dec; 22(12):2080-2087. PubMed ID: 30030718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intraoperative blood transfusion on short and long term outcomes after curative hepatectomy for intrahepatic cholangiocarcinoma: a propensity score matching analysis by the AFC-IHCC study group.
    Gómez-Gavara C; Doussot A; Lim C; Salloum C; Lahat E; Fuks D; Farges O; Regimbeau JM; Azoulay D
    HPB (Oxford); 2017 May; 19(5):411-420. PubMed ID: 28122668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score-Matched Analysis.
    Ecker BL; Vining CC; Roses RE; Maggino L; Lee MK; Drebin JA; Fraker DL; Vollmer CM; Datta J
    Ann Surg Oncol; 2017 Dec; 24(13):3926-3933. PubMed ID: 28952140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
    Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
    J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
    Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
    JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
    Wirasorn K; Ngamprasertchai T; Khuntikeo N; Pakkhem A; Ungarereevittaya P; Chindaprasirt J; Sookprasert A
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1885-91. PubMed ID: 23829232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis.
    Kamarajah SK; Bednar F; Cho CS; Nathan H
    Cancer; 2021 Apr; 127(8):1266-1274. PubMed ID: 33320344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.